Devices, Systems and Methods for Treatment of Abnormal Tissue Using Pulsed Electric Fields
Summary
USPTO granted Patent US12599432B2 to Galvanize Therapeutics, Inc. for devices, systems, and methods to treat abnormal tissue using pulsed electric field (PEF) energy. The patent covers non-thermal energy delivery that preserves extracellular matrices, blood vessels, and lymphatics while treating tumors, cysts, or diseased tissue. The 26 claims span filing date October 15, 2021, under application number 17502640.
What changed
USPTO granted Patent US12599432B2 to Galvanize Therapeutics, Inc. for medical devices and methods treating abnormal tissue through pulsed electric field (PEF) energy delivery. The patent protects technology that delivers non-thermal energy below thermal ablation thresholds while preserving extracellular matrices and structural architecture including blood vessels and lymphatics.
For medical device manufacturers and healthcare technology developers, this patent establishes intellectual property protection for Galvanize Therapeutics in the pulsed electric field tissue treatment space. Companies developing similar PEF-based ablation or tissue treatment technologies should conduct freedom-to-operate analyses to assess potential infringement risks.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Devices, systems and methods for the treatment of abnormal tissue
Grant US12599432B2 Kind: B2 Apr 14, 2026
Assignee
Galvanize Therapeutics, Inc.
Inventors
Seth S. Gleiman, Nicholas S. Mercer, Timothy J. O'Brien, Jonathan R. Waldstreicher, Kevin J. Taylor, Luis L. Mangual Arbelo, Robert E. Neal, William Sanford Krimsky, Quim Castellvi
Abstract
Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.
CPC Classifications
A61B 2018/00267 A61B 2018/00613 A61B 2018/1253 A61B 18/1492 A61B 18/16 A61B 2018/167
Filing Date
2021-10-15
Application No.
17502640
Claims
26
Related changes
Get daily alerts for USPTO Patent Grants - Diagnosis & Surgery (A61B)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Diagnosis & Surgery (A61B) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.